BioWorld

Oct. 13, 2005

Range Of Reasons For Animal Cloning: Heroic To Narcissistic

Celldex Buying Two Firms; IPO Plans Still On Horizon

Positive Tadalafil Data In BPH Starts Phase III Plans For ICOS

Lilly ICOS LLC plans to move tadalafil into a Phase III program for benign prostatic hyperplasia after it reached statistical significance in a Phase II proof-of-concept study. (BioWorld Today) Read More

Raven's Series D: $48M For RAV12 Cancer Trials

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

BioWorld

Oct. 13, 2005

Range Of Reasons For Animal Cloning: Heroic To Narcissistic

Celldex Buying Two Firms; IPO Plans Still On Horizon

Other News To Note

Appointments And Advancements

Positive Tadalafil Data In BPH Starts Phase III Plans For ICOS

Raven's Series D: $48M For RAV12 Cancer Trials

Today's news in brief

Today's news in brief

Cell/gene therapy sector now sustainable; China competition mounting

Neurotrimin unveiled as marker in intellectual disability

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal